Andrea Gotschi

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

In search of a window of opportunity in axial spondyloarthritis: treatment outcomes across different symptom durations.

In search of a window of opportunity in axial spondyloarthritis: treatment outcomes across different symptom durations.

Journal: EULAR rheumatology open

Published: August 01, 2026

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Journal: EULAR rheumatology open

Published: June 29, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Journal: Joint bone spine

Published: May 13, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Journal: Joint bone spine

Published: May 13, 2026

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry.

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry.

Journal: RMD open

Published: April 08, 2026

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Journal: Clinical and experimental rheumatology

Published: February 27, 2026

Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry.

Effectiveness of TNF inhibitors in patients with very early axial spondyloarthritis, defined as duration of ≤1 year of back pain: longitudinal observational data from the SCQM registry.

Journal: RMD open

Published: December 15, 2025

Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort.

Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort.

Journal: Clinical rheumatology

Published: December 23, 2024

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries.

Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries.

Journal: Arthritis research & therapy

Published: July 13, 2024

Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.

Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.

Journal: The Cochrane database of systematic reviews

Published: September 08, 2023

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.

Journal: RMD open

Published: July 01, 2023

Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.

Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.

Journal: Thrombosis research

Published: June 25, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026